Blog
RSS FeedPosted by Michael Wonder on 27 Dec 2021
Ligand’s Partner CStone Pharmaceuticals receives approval in China for sugemalimab (Cejemly) for the first-line treatment of advanced non-small-cell lung cancer in combination with chemotherapy
22 December 2021 - Sugemalimab was discovered using the OmniAb platform. ...
Posted by Michael Wonder on 18 Dec 2021
Chinese official a ‘hero’ after forcing US drug maker Biogen to cut cost of treatment for spinal disease with ‘gentle but firm’ approach
6 December 2021 - US pharmaceutical company reduces the price of a drug for a rare spinal disease after seven rounds ...
Posted by Michael Wonder on 14 Dec 2021
New hope offered to rare disease patients
14 December 2021 - Early this month, the world's first therapy to treat spinal muscular atrophy, a rare genetic disorder ...
Posted by Michael Wonder on 11 Dec 2021
Junshi Biosciences announces NMPA accepted supplemental new drug application for toripalimab in combination with chemotherapy as first-line treatment of advanced NSCLC
10 December 2021 - Sixth indication for toripalimab submitted in China. ...
Posted by Michael Wonder on 09 Dec 2021
Henlius' fourth biologic bevacizumab biosimilar approved by National Medical Products Administration
3 December 2021 - Shanghai Henlius Biotech announced that bevacizumab biosimilar, developed and manufactured by Henlius independently, has been approved by ...
Posted by Michael Wonder on 09 Dec 2021
InnoCare announces inclusion of orelabrutinib in China National Reimbursement Drug List
2 December 2021 - InnoCare Pharma announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement ...
Posted by Michael Wonder on 09 Dec 2021
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA as first COVID-19 neutralising antibody combination therapy in China
8 December 2021 - The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, through a randomised, double-blind ...
Posted by Michael Wonder on 07 Dec 2021
Zai Lab announces inclusion of Zejula (niraparib) in China’s National Reimbursement Drug List for first-line ovarian cancer
3 December 2021 - Zai Lab today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration ...
Posted by Michael Wonder on 07 Dec 2021
China clears insurance coverage for Kainos Medicine’s HIV drug
6 December 2021 - A home-grown HIV treatment developed by Kainos Medicine and out-licensed to China’s Jiangsu Aidea Pharmaceuticals has ...
Posted by Michael Wonder on 07 Dec 2021
Ascletis announces inclusion in new catalogue of China National Reimbursement Drug List of Asclevir/Ganovo regimen, an all oral direct anti-HCV therapy
2 December 2021 - Ascletis Pharma today announces that its all-oral direct anti-hepatitis C virus Asclevir (ravidasvir)/Ganovo (danoprevir) regimen has been ...
Posted by Michael Wonder on 07 Dec 2021
BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of tislelizumab in three new indications, Brukinsa (zanubrutinib) in one new indication, and the first listing for pamiparib
2 December 2021 - BeiGene today announced that three of its medicines have been added to the most recent National Reimbursement ...
Posted by Michael Wonder on 07 Dec 2021
Junshi Biosciences announces two additional indications for toripalimab included in China’s National Reimbursement Drug List
3 December 2021 - The only anti-PD-1 monoclonal antibody in the NRDL for melanoma and nasopharyngeal carcinoma. ...
Posted by Michael Wonder on 04 Dec 2021
Drug makers cut prices by 62% on average to get China state insurance listing
4 December 2021 - Pharmaceutical firms have agreed to cut prices by 61.7% on average for 67 medicines to be ...
Posted by Michael Wonder on 03 Dec 2021
TOT Biopharm announces NMPA granted marketing approval for Pusintin (TAB008, bevacizumab) in China
1 December 2021 - TOT Biopharm announced its self-developed Pusintin (TAB008, bevacizumab) has been officially granted approval by the National ...
Posted by Michael Wonder on 30 Nov 2021
Junshi Biosciences announces approval of supplemental new drug application by NMPA for toripalimab in combination with cisplatin and gemcitabine as first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma
30 November 2021 - Fourth approved indication for toripalimab. ...